Phase 3 data for Retatrutide is expected to clarify whether the 24.2% Phase 2 result is reproducible at scale, potentially making it the most effective single compound in this class
Clinical trials have shown participants using Semaglutide can lose an average of 15% of their body weight after 68 weeks
Key results: Average weight loss: 14.9 percent (approximately 33 pounds for a 220-pound individual) 50 percent of participants lost at least 15 percent of body weight 32 percent of participants lost at least 20 percent Significant improvements in waist circumference, blood pressure, HbA1c, and quality of life Brand Names and Availability Semaglutide is marketed as Ozempic for type 2 diabetes and Wegovy for weight loss
* In this article we is used as a reference to the group of scientists, dieticians, and technical staff in my department who contributed to own studies cited, and the key collaborating scientists from other labs including Jens Juul Holst and John Blundell
The short answer, as of April 2026, is that tirzepatide itself has no swallowable version but the broader oral GLP-1 category is real, growing, and worth understanding before you assume a pill is off the table
10.1016/j.obmed.2025.100619 Obesity Med